Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq:SNDX) granted stock option inducement awards under Nasdaq Listing Rule 5635(c)(4) to four new employees on June 1, 2026. The options cover up to 66,700 shares of common stock under the 2023 Inducement Plan and vest over four years.

AI-generated analysis. Not financial advice.

Key Figures

Inducement options granted: 66,700 shares Employees receiving grants: 4 employees Vesting period: 4 years +5 more

8 metrics

Inducement options granted 66,700 shares Stock options to four new employees under 2023 Inducement Plan

Employees receiving grants 4 employees New hires receiving inducement awards

Vesting period 4 years Stock options vest over four years

Initial cliff vesting 25% Vests on one-year anniversary of vesting commencement date

Ongoing vesting rate 1/48 of shares monthly Monthly vesting over remaining 36 months

Inducement plan year 2023 Grants made under the Company’s 2023 Inducement Plan

Grant date June 1, 2026 Date inducement awards were granted

Listing rule reference Rule 5635(c)(4) Nasdaq Listing Rule governing inducement grants disclosure

Market Reality Check

Price: $18.34 Vol: Volume 1,245,258 is sligh...

normal vol

$18.34 Last Close

Volume Volume 1,245,258 is slightly below the 1,383,922 share 20-day average, indicating typical trading interest ahead of this HR-focused update. normal

Technical Shares at 18.34 are trading below the 200-day MA of 19.38 and about 28.33% under the 52-week high of 25.59.

Peers on Argus

Peer moves were mixed, with BHVN up 8.58% and ARDX down 1.99%, while others were...

1 Up

Peer moves were mixed, with BHVN up 8.58% and ARDX down 1.99%, while others were flat to modestly positive, suggesting stock-specific rather than sector-driven dynamics.

Historical Context

5 past events · Latest: Jun 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jun 02	Clinical data update	Positive	-0.3%	Reported strong Revuforj post‑transplant survival and PK data from ASCO 2026.
Jun 01	R&D day announcement	Positive	-3.8%	Announced July R&D Day to highlight late‑stage and early‑stage oncology assets.
May 21	ASCO abstracts news	Positive	+0.9%	Four Revuforj abstracts, including oral post‑transplant data, accepted for ASCO.
May 20	Conference participation	Positive	+3.6%	Announced participation in several major investor healthcare conferences.
May 12	EHA abstracts news	Positive	-4.5%	Highlighted 12 Revuforj abstracts accepted for EHA 2026 across AML settings.

Pattern Detected

Positive clinical and corporate news has often seen mixed-to-negative next-day price reactions, indicating a tendency toward divergence.

Recent Company History

Over the last few weeks, Syndax has focused on showcasing Revuforj® data and its broader oncology portfolio. Updates included multiple Revuforj abstracts at ASCO 2026 and EHA 2026, post‑transplant survival data, and an announcement of a July 14 R&D Day. These events were generally positive scientifically but produced varied price reactions, with several instances of declines after favorable news. Today’s inducement grants fit into an ongoing pattern of expanding talent and infrastructure around late‑stage and commercial programs.

Market Pulse Summary

This announcement details standard inducement stock option grants covering 66,700 shares for four ne...

Analysis

This announcement details standard inducement stock option grants covering 66,700 shares for four new employees, vesting over 4 years with a 25% one-year cliff and monthly vesting thereafter. It follows a series of data-driven and corporate updates around Revuforj® and broader oncology programs. The grants modestly expand equity-based compensation and align new hires with shareholder outcomes. Investors may watch future hiring trends, option overhang, and upcoming R&D and clinical milestones for further context.

Key Terms

nasdaq listing rule 5635(c)(4), inducement awards, stock options

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement awards financial

"the Company granted inducement awards to purchase up to 66,700 shares"

Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.

stock options financial

"The stock options will vest over four years, with 25% of the underlying"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1, 2026, the Company granted inducement awards to purchase up to 66,700 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contact

Sharon Klahre 
Syndax Pharmaceuticals, Inc. 
sklahre@syndax.com
Tel 781.684.9827

FAQ

What inducement grants did Syndax (SNDX) announce on June 4, 2026?

Syndax announced stock option inducement awards to purchase up to 66,700 shares for four new employees. According to Syndax, these options were granted under its 2023 Inducement Plan and are intended as employment incentives.

How many shares are covered by Syndax's June 2026 inducement stock options?

The inducement stock options cover up to 66,700 shares of Syndax common stock. According to Syndax, these awards were granted to four new employees as part of its 2023 Inducement Plan and vest over a four-year schedule.

What is the vesting schedule for Syndax (SNDX) June 2026 inducement options?

Syndax’s inducement options vest over four years, with 25% vesting after one year. According to Syndax, the remaining 75% vests in equal monthly installments over the next 36 months, subject to continued service with the company.

Why did Syndax use Nasdaq Listing Rule 5635(c)(4) for the June 2026 grants?

Syndax used Nasdaq Listing Rule 5635(c)(4) to grant stock options as inducement awards for new employees. According to Syndax, these options were issued under its 2023 Inducement Plan specifically in connection with new hire employment.

Who is eligible to receive the June 2026 Syndax inducement awards?

Four new Syndax employees are eligible for the June 2026 inducement awards. According to Syndax, each employee’s options are subject to the four-year vesting schedule and require continued service to receive future vested shares.